Document Detail


Octreotide in the management of chemoradiotherapy-induced diarrhea refractory to loperamide in patients with rectal carcinoma.
MedLine Citation:
PMID:  17873499     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To evaluate the efficacy of octreotide in the treatment of chemoradiotherapy (CRT)-induced diarrhea (CRTID) refractory to conventional loperamide treatment in this pilot study. METHODS: Forty-two rectal carcinoma (T(3-4)N(0-2)M(0)) patients with grade 2 or 3 diarrhea refractory to loperamide were enrolled to receive octreotide. Eligible patients were treated with pelvic radiotherapy combined with bolus 5- fluorouracil CRT. Octreotide was administered subcutaneously, 150 microg three times daily, for 5 consecutive days. Only complete resolution of diarrhea was considered as therapeutic success. RESULTS: Diarrhea mainly occurred in the first 4 weeks of CRT (83.3%) and completely resolved in 34 patients (80.9%) following octreotide administration. Mean time to response was 2.7 days: 27 patients (64%) responded during the first 3 days, and the remaining 7 (17%) on days 4 and 5. No significant side effect was reported. Eight patients (19.1%) with refractory diarrhea were hospitalized for additional treatment. No treatment delay was reported in complete responders, whereas an average 7.7-day delay was observed in refractory patients. Antidiarrheal treatment was administered on an outpatient basis in the response group, whereas refractory patients were hospitalized for an average of 8.8 days. CONCLUSION: Daily subcutaneous octreotide administration (150 microg t.i.d.) for 5 days is apparently an effective, tolerable treatment modality for concurrent CRTID refractory to loperamide.
Authors:
Erkan Topkan; Aziz Karaoglu
Related Documents :
22952109 - Total glossectomy with laryngeal preservation and free flap reconstruction: objective f...
17197959 - Early endoscopic intervention versus early conservative management in patients with acu...
19730769 - Prospective randomized pilot trial comparing closed suction drainage and gravity draina...
16500389 - Efficacy and safety of therapeutic ercp in patients 90 years of age and older.
24635169 - Comparative effectiveness of advanced wound dressings for patients with chronic venous ...
24446779 - Comparison of tissue-engineered and artificial dermis grafts after removal of basal cel...
24387929 - Bladder neck sling suspension during robot-assisted radical prostatectomy to improve ea...
24806319 - Microvascular anastomosis using ankaferd blood stopper: demonstration of long-term hist...
20163079 - Topography-guided transepithelial surface ablation followed by corneal collagen cross-l...
Publication Detail:
Type:  Clinical Trial; Journal Article     Date:  2007-09-17
Journal Detail:
Title:  Oncology     Volume:  71     ISSN:  1423-0232     ISO Abbreviation:  Oncology     Publication Date:  2006  
Date Detail:
Created Date:  2007-10-15     Completed Date:  2007-11-09     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0135054     Medline TA:  Oncology     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  354-60     Citation Subset:  IM    
Copyright Information:
Copyright 2006 S. Karger AG, Basel.
Affiliation:
Department of Radiation Oncology, Inonu University Turgut Ozal Medical Center, Malatya, Turkey. drerkantopkan@yahoo.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Antineoplastic Agents / administration & dosage,  adverse effects
Carcinoma / drug therapy*,  radiotherapy*
Combined Modality Therapy / adverse effects
Diarrhea / drug therapy*,  etiology
Dose-Response Relationship, Drug
Drug Administration Schedule
Drug Resistance
Female
Fluorouracil / administration & dosage,  adverse effects
Humans
Injections, Subcutaneous
Loperamide / therapeutic use*
Male
Middle Aged
Octreotide / administration & dosage,  adverse effects,  therapeutic use*
Pilot Projects
Prospective Studies
Radiotherapy, Conformal / adverse effects
Rectal Neoplasms / drug therapy*,  radiotherapy*
Treatment Outcome
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 51-21-8/Fluorouracil; 53179-11-6/Loperamide; 83150-76-9/Octreotide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Interferon-alpha influences tryptophan metabolism without inducing psychiatric side effects.
Next Document:  Hemodynamic effects of local anesthetics with adrenaline during septal surgery